

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Osamu HONMOU et al.

Title: INTERNALLY ADMINISTERED THERAPEUTIC AGENTS FOR CRANIAL NERVE
 DISEASES COMPRISING MESENCHYMA CELLS AS AN ACTIVE INGREDIENT
(As Amended)

International Appl. No.: PCT/JP2004/009386

International Filing Date: 6/25/2004

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. A copy of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Dec. 22, 2005

By Stephen B. Maebius

FOLEY & LARDNER LLP

Customer Number: **22428**

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Stephen B. Maebius

Attorney for Applicant

Registration No. 35,264

10/562202
MODIFIED PTO/SB/08 (08-00)Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCEUnder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
APPROVED PTO 23 DEC 2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: December 23, 2005

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	Unassigned
Filing Date	December 23, 2005
First Named Inventor	Osamu HONMOU
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	033873-0108

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1		JP 2004-544234 A		HENRY FORD HEALTH SYSTEM	12/24/2002		
	A2		WO 01/66698 A1		CRYO-CELL INT. INC.	9/13/2001		
	A3		WO 03/25167 A2		CENT TRANSLATIONAL RES IN CANCER	3/27/2003		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	DATABASE BIOSIS ON STN, (Last Updated on Stn: 6/19/2003) abstract no. 200300283245 & S. IIHOSHI et al., "Intravenous administration of autologous bone marrow cells repairs the ischemic lesions in the rat middle cerebral artery occlusion model", Society for Neuroscience Abstract Viewer & Itinerary Planner, (2002), vol. 2002, abstract no. 237.8., http://sfm.scholarone.com	
	A5	D. LU et al., "Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate to brain and improve neurological outcome", Neuroreport, 2001, vol. 12, No. 3, pp. 559-563.	
	A6	J. CHEN et al., "Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats", Stroke, 2001, Vol. 32, No. 4, pp. 1005-1011.	
	A7	K. CHU et al., "Human neural stem cells can migrate, differentiate and integrate after intravenous transplantation in adult rats with transient forebrain ischemia", Neurosci. Lett., 6/5/2003, Vol. 343, No. 2, pp. 129-133.	
	A8	Y. AKIYAMA et al., "Remyelination of the spinal cord following intravenous delivery of bone marrow cells", Glia., (2002), Vol. 39, pp. 229-236.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1518208.1

10/562202

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: December 23, 2005

(use as many sheets as necessary)

Sheet 2 of 2

Application Number

Unassigned

Filing Date

December 23, 2005

First Named Inventor

Osamu HONMOU

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

033873-0108

IAP9 PTO 23 DEC 2005

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A9	A. MAHMOOD et al., "Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells", Neurosurgery, 2002, vol. 49, no. 5, pp. 1196-1203.	
	A10	DATABASE MEDLINE ON STN, (2002), abstract no. 2002333228 & D. LU et al., "Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury", Cell Transplant. (2002), Vol. 11, No. 3, pp. 275-281.	
	A11	DATABASE BIOSIS ON STN, (2001), abstract no. 200100547979 & Y. AKIYAMA et al., "Remyelination of spinal cord axons by intravenous delivery of bone marrow cells", Society for Neuroscience Abstracts, 2001, Vol. 27, No. 2, pg. 1562.	
	A12	DATABASE BIOSIS IN STN, (2003), abstract no. 200300315449 & P. LU et al., "Transplantation of bone marrow stromal cells (MSCs) and BDNF-transducer MSCs promotes robust axonal growth after spinal cord injury", Society for Neuroscience Abstract Viewer & Itinerary Planner, 2002, Vol. 202, abstract no. 634.11 http://sfn.scholarone.com .	
	A13	MA KEANE-MOORE et al., "Human mesenchymal stem cells can be genetically modified to function as antigen presenting cells", Blood, (1998), Vol. 92, No. 10, suppl. 1, part 1 to 2, pg. 338A, Abstract #1388.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH_1518208.1